NASDAQ:BLTE Belite Bio (BLTE) Stock Forecast, Price & News $31.50 +2.30 (+7.88%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$29.37▼$31.6950-Day Range$14.40▼$36.6452-Week Range$11.00▼$38.63Volume42,944 shsAverage Volume91,168 shsMarket Capitalization$857.75 millionP/E RatioN/ADividend YieldN/APrice Target$41.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Belite Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside30.2% Upside$41.00 Price TargetShort InterestHealthy0.14% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.01Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.27) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector208th out of 965 stocksBiotechnology Industry2nd out of 15 stocks 4.5 Analyst's Opinion Consensus RatingBelite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.00, Belite Bio has a forecasted upside of 30.2% from its current price of $31.50.Amount of Analyst CoverageBelite Bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.14% of the outstanding shares of Belite Bio have been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Belite Bio has recently increased by 7.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBelite Bio does not currently pay a dividend.Dividend GrowthBelite Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLTE. Previous Next 2.2 News and Social Media Coverage News SentimentBelite Bio has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Belite Bio this week, compared to 0 articles on an average week.Search Interest5 people have searched for BLTE on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Belite Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -82% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Belite Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.82% of the stock of Belite Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Belite Bio are expected to grow in the coming year, from ($1.27) to ($0.50) per share.Price to Book Value per Share RatioBelite Bio has a P/B Ratio of 18.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Belite Bio (NASDAQ:BLTE) StockBelite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.Read More BLTE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLTE Stock News HeadlinesSeptember 20, 2023 | americanbankingnews.comBelite Bio, Inc (NASDAQ:BLTE) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 22, 2023 | seekingalpha.comBelite Bio: The Pick Of The Post-IPO Biotechs - Is There Further Upside Ahead?September 23, 2023 | Altimetry (Ad)Seven millionaires secretly enable market shock?A fraud expert to the FBI just shared a surprising new prediction. Own stocks? Watch it now.August 13, 2023 | seekingalpha.comBelite Bio, Inc 2023 Q2 - Results - Earnings Call PresentationAugust 12, 2023 | fool.comBelite Bio (NASDAQ: BLTE)August 11, 2023 | markets.businessinsider.comExpert Ratings for Belite BioAugust 8, 2023 | finance.yahoo.comBelite Bio Reports Second Quarter 2023 Operational Highlights and Financial ResultsAugust 4, 2023 | finance.yahoo.comBelite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial ResultsSeptember 23, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.July 31, 2023 | finance.yahoo.comIs Belite Bio, Inc (NASDAQ:BLTE) Worth US$24.1 Based On Its Intrinsic Value?July 29, 2023 | markets.businessinsider.comBelite Bio Incorporation American Depository Receipt Repr 1 ShJuly 28, 2023 | finance.yahoo.comBelite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GAJuly 27, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Belite BioJuly 24, 2023 | finance.yahoo.comBelite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt DiseaseJune 30, 2023 | finance.yahoo.comWhy Shares of Belite Bio Soared This WeekJune 20, 2023 | markets.businessinsider.comAnalyst Expectations for Belite Bio's FutureJune 15, 2023 | seekingalpha.comBelite Bio: Undercovered Eye Disease Company With Early DataMay 31, 2023 | finance.yahoo.comWhy Shares of Belite Bio Are Slumping WednesdayMay 31, 2023 | msn.comBelite Bio down 38%, prices $30M offeringMay 31, 2023 | marketwatch.comBelite Bio ADSs Plunge Premarket After Public Offering Priced >BLTEMay 31, 2023 | finance.yahoo.comBelite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and WarrantsMay 30, 2023 | msn.comBelite Bio commences public offering of American Depositary SharesMay 30, 2023 | finance.yahoo.comBelite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and WarrantsMay 14, 2023 | seekingalpha.comBelite Bio, Inc 2023 Q1 - Results - Earnings Call PresentationMay 11, 2023 | finance.yahoo.comBelite Bio Reports First-Quarter 2023 Operational Highlights and Financial ResultsMay 10, 2023 | finance.yahoo.comBelite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial ResultsMay 4, 2023 | finance.yahoo.comBelite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 DataSee More Headlines Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLTE Company Calendar Last Earnings8/08/2023Today9/23/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLTE CUSIPN/A CIK1889109 Webbelitebio.com Phone858-246-6240FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Forecast$41.00 High Stock Price Forecast$57.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+30.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio20.35 Quick Ratio20.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book18.86Miscellaneous Outstanding Shares27,230,000Free Float23,610,000Market Cap$857.75 million OptionableNot Optionable Beta-2.10 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Yu-Hsin Lin M.B.A. (Age 44)Ph.D., Chairman of Directors & CEO Mr. Hao-Yuan Chuang C.F.A. (Age 39)F.R.M., M.B.A., CFO & Director Dr. Nathan L. Mata Ph.D. (Age 57)Chief Scientific Officer Key CompetitorsTango TherapeuticsNASDAQ:TNGXArdelyxNASDAQ:ARDXVerve TherapeuticsNASDAQ:VERVInnovivaNASDAQ:INVANewAmsterdam PharmaNASDAQ:NAMSView All CompetitorsInstitutional OwnershipState Street CorpBought 921 shares on 8/14/2023Ownership: 0.049%Atria Wealth Solutions Inc.Bought 2,733 shares on 8/3/2023Ownership: 3.268%View All Institutional Transactions BLTE Stock - Frequently Asked Questions Should I buy or sell Belite Bio stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLTE shares. View BLTE analyst ratings or view top-rated stocks. What is Belite Bio's stock price forecast for 2023? 6 Wall Street research analysts have issued 1 year price targets for Belite Bio's stock. Their BLTE share price forecasts range from $25.00 to $57.00. On average, they anticipate the company's share price to reach $41.00 in the next year. This suggests a possible upside of 30.2% from the stock's current price. View analysts price targets for BLTE or view top-rated stocks among Wall Street analysts. How have BLTE shares performed in 2023? Belite Bio's stock was trading at $30.1450 at the beginning of the year. Since then, BLTE shares have increased by 4.5% and is now trading at $31.50. View the best growth stocks for 2023 here. Are investors shorting Belite Bio? Belite Bio saw a increase in short interest in August. As of August 31st, there was short interest totaling 37,500 shares, an increase of 7.1% from the August 15th total of 35,000 shares. Based on an average daily volume of 81,900 shares, the days-to-cover ratio is currently 0.5 days. View Belite Bio's Short Interest. When is Belite Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our BLTE earnings forecast. How were Belite Bio's earnings last quarter? Belite Bio, Inc (NASDAQ:BLTE) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.03. When did Belite Bio IPO? (BLTE) raised $36 million in an initial public offering on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share. What is Belite Bio's stock symbol? Belite Bio trades on the NASDAQ under the ticker symbol "BLTE." Who are Belite Bio's major shareholders? Belite Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Atria Wealth Solutions Inc. (3.27%) and State Street Corp (0.05%). How do I buy shares of Belite Bio? Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Belite Bio's stock price today? One share of BLTE stock can currently be purchased for approximately $31.50. How much money does Belite Bio make? Belite Bio (NASDAQ:BLTE) has a market capitalization of $857.75 million. How can I contact Belite Bio? The official website for the company is belitebio.com. The company can be reached via phone at 858-246-6240 or via email at ir@belitebio.com. This page (NASDAQ:BLTE) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.